Canada Markets closed

Amryt Pharma plc (AMYT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.99-0.10 (-1.41%)
At close: 04:00PM EDT
6.99 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close7.09
Open6.81
Bid6.82 x 1200
Ask7.44 x 2200
Day's Range6.81 - 7.19
52 Week Range5.61 - 12.49
Volume84,231
Avg. Volume77,716
Market Cap447.101M
Beta (5Y Monthly)0.36
PE Ratio (TTM)N/A
EPS (TTM)-2.24
Earnings DateMar 02, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.17
  • GlobeNewswire

    Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

    Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Dr Tracy Cunningham as Chief Medical officer (CMO) with immediate effect. Dr Cunningham joined Amryt in April 2020 as VP, Head of Development with responsibility for pre-

  • GlobeNewswire

    Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA

    Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA Filsuvez® recently approved by the European Commission for the treatment of EB DUBLIN, Ireland, and Boston MA, June 24, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, today announces that the company plans to submit a Formal Dispute Resolution Request (FDRR) for the company’s New Drug Application (NDA

  • GlobeNewswire

    European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB

    European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB Filsuvez® will be the first and only approved treatment for EB Patients DUBLIN, Ireland, and Boston MA, June 23, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the European Commission (EC) approval of Filsuvez® in the European Union (EU) for the treatment of parti